employer coverage glp-1 news october 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford GLP-1 Coverage Debate Comes Down

There are ample studies on the efficacy of GLP-1 agonists and lifestyle changes in helping people to lose weight, with outcomes that range from 10 pounds to 33 pounds or more

As a result, many, including us at diaTribe, had expected Bydureon to gain approval this second time around, especially given the promising results indicated above and the apparent lack of notable safety concerns

Its also important to point out that probably the most important things for longevity are quite simple: exercise, eating a plant-based diet, sleep, and stress management

In vivo, GLP-1 has a half-life of only 23 min, preventing its therapeutic utilisation 31,32,33,34,35

GLP-1/GIP therapy (Tirzepatide) activates both GLP-1 and GIP receptors often delivering stronger appetite control and metabolic benefits